Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) have received an average rating of “Buy” from the six ...

Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Capricor Therapeutics in a research ...

Shares of Capricor Therapeutics CAPR gained 8.4% on Thursday following the completion of the submission of a biologics license application (BLA) to the FDA seeking full approval for deramiocel to ...

Capricor Therapeutics (CAPR) closed the last trading session at $13.47, gaining 7.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...

Capricor Therapeutics (CAPR) announced the completion of the submission of its Biologics License Application, BLA, to the U.S. Food and Drug ...

JonesResearch says shares of Capricor Therapeutics (CAPR) saw some volatility over an FDA warning letter issued to an investigator involved in the deramiocel HOPE-3 study, Dr. Phan. After ...

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of biological therapies for the treatment of cardiac and other serious medical conditions. Its product ...

America's Car-Mart Posts Upbeat Sales, Joins Methode Electronics, Verint Systems, Brown-Forman And Other Big Stocks Moving Higher On Thursday Why Capricor Therapeutics (CAPR) Shares Are Trading ...

Ratings for Capricor Therapeutics CAPR were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table ...

Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shareholders might understandably be very concerned that the share ...

Capricor Therapeutics (CAPR) announced the completion of the submission of its Biologics License Application, BLA, to the U.S. Food and Drug Administration, FDA, seeking full approval for ...